EMCURE — Emcure Pharmaceuticals Balance Sheet
0.000.00%
- IN₹252.77bn
- IN₹262.01bn
- IN₹78.96bn
- 91
- 13
- 94
- 76
Annual balance sheet for Emcure Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 5,235 | 3,084 | 4,468 | 5,174 | 2,939 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 16,204 | 15,157 | 19,024 | 21,133 | 20,022 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 37,175 | 34,241 | 38,359 | 42,599 | 45,559 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 19,332 | 19,855 | 22,148 | 23,972 | 24,271 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 68,074 | 60,635 | 66,725 | 78,062 | 82,327 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 34,082 | 29,648 | 30,192 | 32,105 | 26,683 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 45,344 | 40,759 | 41,714 | 48,539 | 37,865 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 22,730 | 19,875 | 25,011 | 29,523 | 44,462 |
Total Liabilities & Shareholders' Equity | 68,074 | 60,635 | 66,725 | 78,062 | 82,327 |
Total Common Shares Outstanding |